Evaluation Of The Chronic Effects Of Covıd-19 Infection On The Respiratory System

COVID-19 Clinical Trial

Official title:

Evaluation Of The Chronic Effects Of Covıd-19 Infection On The Respiratory System By Pulmonary Ultrasound, Pulmonary Function Tests and Cytokine Level Measurement

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06439134
• Other study ID #: Inflammation and Post COVID-19
• Status: Completed
• Start date: June 1, 2022
• Est. completion date: September 1, 2023

Study information

• Verified date: April 2024
• Source: Yeditepe University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The aim of this study is to evaluate whether there are chronic effects in the pulmonary system and systemic level in individuals in the post COVID19 period in order to elucidate the involvement of inflammation after recovery. In addition, a perspective on the utility of pulmonary function testing and pulmonary ultrasound in the evaluation of chronic effects and patient follow-up will is aimed to be provided. By measuring the protein levels of inflammatory markers along with the data abovementioned, a foresight regarding the long-term effects of the previous infection at both functional and immunological levels will be obtained, allowing us to evaluate the post-COVID period from different angles.

Volunteers who recovered from COVID-19 and those who didn't have COVID-19 were compared by evaluating chest x-ray scores (CXR), lung ultrasound scores (LUSS), pulmonary function tests and inflammatory cytokine levels (TNF-α, IL-1, IL-6, IL-17A).

Description:

Objective: The aim of this study is to evaluate whether there are chronic effects in the pulmonary system and systemic level in individuals in the post COVID19 period in order to elucidate the involvement of inflammation after recovery. In addition, a perspective on the utility of pulmonary function testing and pulmonary ultrasound in the evaluation of chronic effects and patient follow-up will is aimed to be provided. By measuring the protein levels of inflammatory markers along with the data abovementioned, a foresight regarding the long-term effects of the previous infection at both functional and immunological levels will be obtained, allowing us to evaluate the post-COVID period from different angles.

Materials and Methods: Volunteers who recovered from COVID-19 infection at least 3 months or more were included in the study, while healthy volunteers who did not have the infection were enrolled as the control group. Two groups were compared by evaluating chest x-ray scores (CXR), lung ultrasound scores (LUSS), pulmonary function tests and inflammatory cytokine levels (TNF-α, IL-1, IL-6, IL-17A).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: September 1, 2023
• Est. primary completion date: June 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:For the control group;

• Age range: 18-60 years old

• Not having had COVID-19 infection

• (For female patients) No pregnancy or puerperium

• Consent for the study

• To be able to complete the pulmonary function test successfully

• Vital signs at the stage of lung ultrasound or pulmonary function testing during the study no change in findings

• Not having an active infection at the time of the workplace examination

• No abnormal findings in the chest radiograph taken before the study

• Absence of existing autoimmune or rheumatological disorders For the experimental group;

• Age range: Being between 18-60 years old

• Having had COVID-19 infection and post infectious period of 3 months or more to be

• (For female patients) No pregnancy or puerperium

• Consent for the study

• To be able to complete the pulmonary function test successfully

• Vital signs at the stage of lung ultrasound or pulmonary function testing during the study no change in findings

• Not having an active infection at the time of the workplace examination

• Abnormal findings on chest radiography taken in the pre-infectious period before the study absence of

• Absence of existing autoimmune or rheumatological disorders

Exclusion Criteria:

• Age range: Being outside the 18-60 age range

• (for the experimental group) COVID-19 infection and 3 days of post infectious period under the month

• (For female patients) Pregnancy or puerperium

• Lack of consent for the study

• Failure to complete the pulmonary function test (dizziness, incompatibility, etc.) reasons)

• Vital signs at the stage of lung ultrasound or pulmonary function testing during the study change in findings

• Having an active infection at the time of the workplace examination

• Abnormal chest radiographs taken in the pre-infectious period before the study the presence of findings

• Existing autoimmune or rheumatological disease

Related Conditions & MeSH terms

• COVID-19
• Post-COVID-19 Syndrome

Intervention

Diagnostic Test:
• Pulmonary Ultrasound, Respiratory Function Test
Volunteers underwent pulmonary ultrasound and respiratory function test

Locations

Country	Name	City	State
Turkey	Yeditepe University	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Yeditepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pulmonary Ultrasound	Pulmonary Ultrasound is going to be made and evaluated by using LUSS score. LUSS score is an evlatuation score for pulmonary ultrasound. For the study, both hemithoraces of the patient will divided into eight areas in total. The evaluation is going to be performed in the right hemithorax upper anterior, right hemithorax lower anterior, right hemithorax upper lateral, right hemithorax lower lateral, left hemithorax upper anterior, left hemithorax lower anterior, left hemithorax upper lateral, and left hemithorax lower lateral regions, respectively. During the assessment, the researcher is going to be positioned on the right side of the patient for the right hemithorax assessment and on the left side for the left hemithorax assessment. Each area will be scored between 0-3 and for final score, score for each zone will be collected . 24 is the worst score and 0 is the best score.	1 month
Primary	Respiratory Function Test	Respiratory Function Test results are going to be recorded. The recorded values will be FEV1, FVC, FEV1/FVC, PEF, FRC and TLC values.	1 month
Primary	Chest X-ray Evaluation	Chest X-ray evaluation is going to be made according to CXR score. During the evaluation of chest radiography, the pulmonary parenchyma is going to be divided into a total of six regions as right/left and apical region/mid region/basal region. Post COVID-19 changes are going to be taken into consideration when scoring criteria is made; 0- No abnormal findings; Interstitial infiltrates (Septal thickening and focal or extensional opacity); Interstitial and alveolar infiltrates (Interstitial predominant); Interstitial and alveolar infiltrates (Alveolar predominance) The criteria looked at as A points will be scored. Each zone is going to be evaluated with a score defined as A score and the scores of each zone is going to be summed to obtain a total score. Thus, each radiograph will be given a score between 0-18 by scoring all six defined zones and an evaluation will be made.	1 month
Primary	Blood Cytokine Result Analysis	Blood Cytokine Result Analysis is going to be made by Cytokine-Bead Array. The measured cytokines will be TNF-a, IL-1, IL-6 and IL-17A	1 month